PD-1 Blockade Aggravates Epstein-Barr Virus
Epstein-Barr Virus (EBV)
PD-1
humanized mice
immune checkpoint inhibition (ICI)
immuno-oncology
lymphoma
pembrolizumab
post-transplant lymphoproliferative disease (PTLD)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
10
2020
accepted:
16
11
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
epublish
Résumé
Post-transplant lymphoproliferative disorder (PTLD) is one of the most common malignancies after solid organ or allogeneic stem cell transplantation. Most PTLD cases are B cell neoplasias carrying Epstein-Barr virus (EBV). A therapeutic approach is reduction of immunosuppression to allow T cells to develop and combat EBV. If this is not effective, approaches include immunotherapies such as monoclonal antibodies targeting CD20 and adoptive T cells. Immune checkpoint inhibition (ICI) to treat EBV
Identifiants
pubmed: 33511078
doi: 10.3389/fonc.2020.614876
pmc: PMC7837057
doi:
Types de publication
Journal Article
Langues
eng
Pagination
614876Informations de copyright
Copyright © 2021 Volk, Theobald, Danisch, Khailaie, Kalbarczyk, Schneider, Bialek-Waldmann, Krönke, Deng, Eiz-Vesper, Dragon, von Kaisenberg, Lienenklaus, Bleich, Keck, Meyer-Hermann, Klawonn, Hammerschmidt, Delecluse, Münz, Feuerhake and Stripecke.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Front Oncol. 2019 Aug 06;9:713
pubmed: 31448229
J Thorac Dis. 2019 Mar;11(Suppl 3):S262-S265
pubmed: 30997192
Med Oncol. 2012 Dec;29(5):3614-9
pubmed: 22791223
Nat Med. 2019 Aug;25(8):1243-1250
pubmed: 31332390
J Immunol. 2010 Jun 1;184(11):6545-51
pubmed: 20421648
Oncotarget. 2017 Jul 4;8(27):44266-44280
pubmed: 28574826
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
Am J Pathol. 2019 Mar;189(3):521-539
pubmed: 30593822
Mol Ther Oncolytics. 2020 Aug 08;18:504-524
pubmed: 32953984
Nat Rev Immunol. 2012 Nov;12(11):786-98
pubmed: 23059428
Blood. 2016 Jun 30;127(26):3331-40
pubmed: 27207801
J Immunother Cancer. 2019 Aug 7;7(1):209
pubmed: 31391096
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Front Immunol. 2017 Dec 08;8:1709
pubmed: 29276513
Blood. 2015 Aug 13;126(7):863-72
pubmed: 25999451
Cancer Immunol Immunother. 2017 May;66(5):551-564
pubmed: 28213726
Immunotherapy. 2019 Feb;11(3):167-175
pubmed: 30730278
Front Immunol. 2018 Nov 22;9:2734
pubmed: 30524448
Am J Hematol. 2018 Jul;93(7):953-962
pubmed: 29984868
Cell Rep. 2013 Oct 31;5(2):458-70
pubmed: 24120866
PLoS Pathog. 2016 May 17;12(5):e1005642
pubmed: 27186886
Bone Marrow Transplant. 2020 Jan;55(1):25-39
pubmed: 31089285
Am J Pathol. 2017 Jun;187(6):1380-1398
pubmed: 28432872
EMBO Mol Med. 2020 Jul 7;12(7):e8662
pubmed: 32578942
Eur J Haematol. 2019 Sep;103(3):200-207
pubmed: 31211907
Cytokine. 2020 Sep;133:155119
pubmed: 32535334
Gastric Cancer. 2019 Jul;22(4):793-802
pubmed: 30627987
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
PLoS Pathog. 2020 Jul 15;16(7):e1008560
pubmed: 32667948
Sci Transl Med. 2019 Jan 16;11(475):
pubmed: 30651320
Front Oncol. 2019 Mar 07;9:109
pubmed: 30899698
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8
pubmed: 20679213
J Thorac Dis. 2019 Mar;11(Suppl 3):S347-S351
pubmed: 30997217
Medicine (Baltimore). 2020 Jan;99(5):e19013
pubmed: 32000444
Hematol Oncol. 2018 Feb;36(1):98-103
pubmed: 28707331
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
Oncotarget. 2017 Feb 7;8(6):10238-10254
pubmed: 28052012
PLoS Pathog. 2019 May 30;15(5):e1007748
pubmed: 31145756
Curr Opin Virol. 2017 Aug;25:113-118
pubmed: 28837889
J Immunol. 2010 Feb 15;184(4):1690-701
pubmed: 20053943
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Am J Pathol. 2008 Nov;173(5):1369-78
pubmed: 18845836
Exp Mol Med. 2015 Jan 23;47:e135
pubmed: 25613732
J Hematol Oncol. 2019 Jun 10;12(1):58
pubmed: 31182108
J Immunol. 2019 Sep 15;203(6):1665-1674
pubmed: 31434708
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683809
Nat Immunol. 2019 Jul;20(7):770-774
pubmed: 31160798
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Blood. 2015 Nov 12;126(20):2274-83
pubmed: 26384356
Hum Gene Ther. 2020 Apr;31(7-8):423-439
pubmed: 32159399
J Oncol. 2019 May 7;2019:9513701
pubmed: 31205470
Virology. 2013 Jul 5;441(2):107-13
pubmed: 23601786
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13081-6
pubmed: 26438862